Markets:

Overview

News

Currencies

International

Treasuries

Intra-Cellular Therapies Inc. - Common Stock (NQ:ITCI)

131.87 UNCHANGED

Last Price Updated: 4:00 PM EDT, Apr 1, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Intra-Cellular Therapies Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

45 Biggest Movers From Yesterday ↗

January 05, 2022

Gainers ATA Creativity Global (NASDAQ: AACG) gained 114.3% to close at $2.55. Hoth Therapeutics, Inc. (NASDAQ: HOTH) surged 85.7% to settle at $1.30 after the company announced...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

January 04, 2022

Gainers Hoth Therapeutics (NASDAQ:

Via Benzinga

34 Stocks Moving In Tuesday's Mid-Day Session ↗

January 04, 2022

Gainers TherapeuticsMD, Inc. (NASDAQ: TXMD) jumped 31.7% to $0.5185 after it announced that the FDA approved a low dose version of Bijuva, an oral hormone therapy to treat women...

Via Benzinga

Analyst Ratings For Intra-Cellular Therapies ↗

December 20, 2021

Within the last quarter, Intra-Cellular Therapies (NASDAQ:ITCI) has observe...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

January 04, 2022

Gainers Plus Therapeutics (NASDAQ:PSTV) shares increased by 68.7% to $1.84 during Tuesday's pre-market session. The market value of their outstanding shares is at $28....

Via Benzinga

23 Stocks Moving in Tuesday's Pre-Market Session ↗

January 04, 2022

Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) rose 62.1% to $1.05 in pre-market trading as the company issued a clinical and corporate update. NeuroBo Pharmaceuticals, Inc...

Via Benzinga

IntraCellular Seeks To Raise $400M Via Equity To Fund Commercialization Of Schizophrenia Med ↗

January 04, 2022

Intra-Cellular Therapies Inc (NASDAQ: ITCI) commenced an underwritten public offering of $400 million of shares. Underwriters have an option to purchase up to an...

Via Benzinga

A Peek Into The Markets: US Stock Futures Up Ahead Of Manufacturing Report ↗

January 04, 2022

Pre-open movers U.S. stock futures traded higher in early pre-market trade after the Dow Jones and S&P 500 closed at fresh highs on the first trading day of new year....

Via Benzinga

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight ↗

August 08, 2021

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,...

Via Benzinga

5 Stocks To Watch For January 4, 2022 ↗

January 04, 2022

Some of the stocks that may grab investor focus today are: Wall Street expects SMART Global Holdings, Inc. (NASDAQ: SGH) to report quarterly earnings at $2.00 per share on...

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

January 03, 2022

Gainers Indaptus Therapeutics (NASDAQ:INDP

Via Benzinga

The Global Breast Cancer Treatment Market Expected To Reach $34.06 Billion By End Of 2026

December 21, 2021

Palm Beach, FL – December 21, 2021 – FinancialNewsMedia.com News Commentary – Breast cancer is cancer that develops in the breast tissue. Breast cancer signs include the formation of a lump in the...

Via FinancialNewsMedia

65 Biggest Movers From Yesterday ↗

December 21, 2021

Gainers Society Pass Incorporated (NASDAQ: SOPA) shares climbed 240.2% to close at $11.26 on Monday after the company reported addition to the Russell 2000 Index. Bluerock...

Via Benzinga

38 Stocks Moving In Monday's Mid-Day Session ↗

December 20, 2021

Gainers Society Pass Incorporated (NASDAQ: SOPA) shares jumped 120.9% to $7.31 after the company reported addition to the Russell 2000 Index. Can-Fite BioPharma Ltd. (NYSE: CANF...

Via Benzinga

FDA Approves Intra-Cellular's Antipsychotic For Bipolar Depression ↗

December 20, 2021

The FDA has approved Intra-Cellular Therapies Inc (NASDAQ: ITCI) Caplyta for depressive episodes associated with bipolar I or II disorder in adults. The approval...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

December 20, 2021

Gainers Intra-Cellular Therapies (NASDAQ:ITCI) stock rose 18.79% to $46.52 during Monday's pre-market session. The market value of their outstanding shares is at $3.7...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

December 20, 2021

The weekend break is over and that means it's time to get back to work with the biggest pre-market stock movers for Monday!

Via InvestorPlace

The Daily Biotech Pulse: Genfit Spikes On Liver Disease Drug Licensing Deal, Lyell Gets Nod For Solid Tumor Study, Decision-Day For Intra-Cellular, Argenx ↗

December 17, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Merck Announces Publication Of Positive Data From Late-Stage Study Of Oral...

Via Benzinga

The Week Ahead In Biotech (Dec. 12-18): Hematology Conference Presentations, FDA Decisions For Calliditas, Argenx, Intra-Cellular & Eagle Pharma And More ↗

December 12, 2021

Biotech stocks closed out the week ending Dec. 10 with modest losses as investors moved money out of defensives and into risky bets amid the broader market rebound. Multiple...

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates ↗

December 02, 2021

A majority of verdicts handed down by the FDA in November were positive. Three new molecular entities were approved during the month, taking the total number of NME approvals for...

Via Benzinga

Looking Into Intra-Cellular Therapies's Return On Capital Employed ↗

November 10, 2021

Benzinga Pro data, Intra-Cellular Therapies (NASDAQ:ITCI) reported Q3 sales of $22.21 million. Earnings fell to a loss of $77.32 million, resulting in a 11.83% decrease from last...

Via Benzinga

Intra-Cellular Therapies inc (ITCI) Q3 2021 Earnings Call Transcript ↗

November 09, 2021

ITCI earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

Intra-Cellular Therapies: Q3 Earnings Insights ↗

November 09, 2021

Intra-Cellular Therapies (NASDAQ:ITCI) reported its Q3 earnings results on Tuesday, November 9, 2021 at 08:00 AM. Here's what investors need to know about the...

Via Benzinga

Two Trillion-Dollar Industries Being Transformed By Tech

October 20, 2021

FN Media Group Presents Oilprice.com Market Commentary London – October 20, 2021 – Big money is pouring into two disruptive segments in two of the world’s biggest industries – healthcare and energy....

Via FinancialNewsMedia

Benzinga's Top Ratings Upgrades, Downgrades For September 23, 2021 ↗

September 23, 2021

Upgrades Barclays upgraded the previous rating for Warner Music Group Corp (NASDAQ:

Via Benzinga

Looking Into Intra-Cellular Therapies's Return On Capital Employed ↗

September 20, 2021

Intra-Cellular Therapies (NASDAQ:ITCI) brought in sales totaling $20.05 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 29.92%, resulting...

Via Benzinga

Why Intra-Cellular Therapies Was Weak This Week ↗

August 13, 2021

The company's second-quarter net loss was a bit deeper than analysts expected.

Via The Motley Fool

Intra-Cellular Therapies inc (ITCI) Q2 2021 Earnings Call Transcript ↗

August 09, 2021

ITCI earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

Intra-Cellular Therapies: Q2 Earnings Insights ↗

August 09, 2021

Shares of Intra-Cellular Therapies (NASDAQ:ITCI) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share rose 11.46% over the past year...

Via Benzinga

Earnings Scheduled For August 9, 2021 ↗

August 09, 2021

Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million. •...

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.